BioNexus Gene Lab Announce The Successful Co-Investment By The Securities Commission Of Malaysia Into Ascension Innovation Sdn Bhd
BioNexus Gene Lab Announce The Successful Co-Investment By The Securities Commission Of Malaysia Into Ascension Innovation Sdn Bhd
BioNexus Gene Lab Corp. (NASDAQ:BGLC), an emerging leader in genomic diagnostics and personalized medicine, is pleased to announce the successful co-investment by the Securities Commission of Malaysia under its Malaysia Co-Investment Fund (MyCIF), into Ascension Innovation Sdn Bhd (AISB). This co-investment, alongside BGLC's recent investment, the first under its Environmental & Social Impact (ESI) Scheme shows confidence in the strategic direction and potential of AISB.
BioNexus Gene Lab corp.（納斯達克：BGLC）是基因組診斷和個性化醫學領域新興領導者，高興地宣佈馬來西亞證券委員會在其馬來西亞共同投資基金（MyCIF）下對Ascension Innovation私人有限公司（AISB）進行成功共同投資。這次共同投資與BGLC最近的首次環保和社會影響（ESI）計劃投資同時進行，顯示了對AISB戰略方向和潛力的信心。
AISB, a pioneering healthcare technology company, has become the first issuer to receive investment under the Environmental & Social Impact (ESI) scheme, part of the broader MyCIF initiative. This scheme, designed to support small and medium enterprises (MSMEs) with impactful solutions, aligns perfectly with AISB's mission to revolutionize healthcare through innovative, sustainable practices.
AISB是一家開拓性的醫療科技公司，成爲首家在環保和社會影響（ESI）計劃下獲得投資的發行人，該計劃是馬來西亞共同投資基金（MyCIF）倡議的一部分。該計劃旨在支持具有影響力解決方案的中小企業（MSMEs），與AISB通過創新可持續實踐改革醫療保健的使命完美契合。
譯文內容由第三人軟體翻譯。
